Delia Mezzanzanica received her Ph.D. degree in tumor biology from The University of Milan, in 1985. Since 2006, she has been Group Leader of the Unit of Molecular Therapies, Department of Experimental Oncology and Molecular Medicine (DOSMM), Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan. From 2004 to 2009, she was a Professor of Biology at The University of Milan. In 1995, she was a Visiting Scientist at the Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. There she worked on cloning of lymphocytic chimeric receptors with antitumor specificity. In 1989, she was a Visiting Fellow at the Experimental Immunology Branch, NCI, NIH, Bethesda, MD, USA. From 1987 to 1998, she was a Research Assistant at the Division of Experimental Oncology, INT, Milan. From 1985 to 1987, she was a Fellow at the Division of Experimental Oncology, INT, Milan. Her areas of expertise include extensive experience and background in immunology, biochemistry, and cellular and molecular biology applied to the field of oncology. She is particularly involved in translational research aimed at the identification of new markers/signaling pathways associated with disease persistence/early relapse in ovarian carcinoma. The research is now focused on the analysis of microRNA expression profile alteration associated with clinical response in advanced-stage ovarian cancer.
Biography Updated on 23 January 2011